Results 71 to 80 of about 681,792 (231)

Supplementary Table S2 from Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors

, 2020
Activity and efficacy data of selective FGFR inhibitors in tumors other than urothelial cancers and cholangiocarcinomas.
Yohann Loriot (342267), Antoine Hollebecque (15010338), Francesco Facchinetti (9588699), Ken A. Olaussen (14882016), Luc Friboulet (15025943), Christophe Massard (120966), Rastislav Bahleda (13011628)   +6 more
core   +1 more source

Inhibition of FGFR Signaling by Targeting FGF/FGFR Extracellular Interactions: Towards the Comprehension of the Molecular Mechanism through NMR Approaches

, 2022
NMR-based approaches play a pivotal role in providing insight into molecular recognition mechanisms, affording the required atomic-level description and enabling the identification of promising inhibitors of protein–protein interactions.
Pagano, Katiuscia, Henriette Molinari, Laura Ragona, Taraboletti, Giulia, Ragona, Laura, Longhi, Elisa, Elisa Longhi, Giulia Taraboletti, Katiuscia Pagano, Molinari, Henriette, Pagano, Henriette, Elisa, Laura, Katiuscia, Giulia, Longhi, Molinari, Ragona, Taraboletti   +19 more
core   +1 more source

Chromosomal Abnormalities, Drug Sensitivity and Resistance in Hematological Malignancies: A Comprehensive Overview by the Francophone Group of Hematological Cytogenetics (GFCH)

American Journal of Hematology, EarlyView.
ABSTRACT Chromosomal abnormalities have a major clinical impact on hematological malignancies, particularly with regard to treatment strategies. To preserve and consolidate fundamental knowledge in this rapidly evolving field, the Francophone Group of Hematological Cytogenetics (Groupe Francophone de Cytogénétique Hématologique, GFCH) conducted a ...
Florence Nguyen‐Khac, Audrey Bidet, Elise Chapiro, Nathalie Douet‐Guilbert, Jean‐Baptiste Gaillard, Nada Assaf, Nathalie Auger, Hend Chaker, Jasmine Chauzeix, Inge Govaerts, Hippolyte Guérineau, Christine Lefebvre, Pauline Roynard, Hélène Guermouche, Lucienne Michaux, Marie‐Bérengère Troadec, Lauren Véronèse   +16 more
wiley   +1 more source

Neurovascular coupling in bone regeneration: Mechanisms, advanced biomaterials and challenges

BMEMat, EarlyView.
This figure illustrates various material strategies for neurovascularized bone regeneration, including electroactive scaffolds, ion‐loaded materials, drug delivery systems, surface modifications, cells/cell products, growth factors, and peptides. These approaches aim to synergistically promote the regeneration of neural, vascular, and bone tissues ...
Yixin Ma, Nan Jiang, Liyuan Chen, He Zhang, Xinjia Cai, Karan Gulati, Danqing He, Zhigang Cai, Yan Liu   +8 more
wiley   +1 more source

Resistance to allosteric SHP2 inhibition in FGFR-driven cancers through rapid feedback activation of FGFR

, 2020
SHP2 mediates RAS activation downstream of multiple receptor tyrosine kinases (RTKs) and cancer cell lines dependent on RTKs are in general dependent on SHP2.
Le, Thi Bich Uyen, Mohseni, Mori, Lu, Henry, Liu, Chen, Engelman, Jeffrey, Caponigro, Giordano, LaMarche, Matthew, Hammerman, Peter, Hao, Huaixiang, Huynh, Hung   +9 more
core   +1 more source

Membrane lipid metabolism as a regulatory frontier in neural crest biology: Roles for sphingolipids, cholesterol, and lipid rafts

Developmental Dynamics, EarlyView.
Abstract Neural crest cells are multipotent, migratory stem‐like cells essential for vertebrate development that contribute broadly to many tissues including the craniofacial skeleton, peripheral nervous system, and pigment‐producing cells. Their development progresses through phases of induction, specification, delamination, migration, and ...
Allison E. Mancini, Mallorie P. Jenne, Michael L. Piacentino   +2 more
wiley   +1 more source

Supplementary Table S1 from Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors

, 2020
Phase I trials of selective FGFR inhibitors encompassing a dose-escalation phase and lacking a precise histologic/molecular selection (with the exception of Debio 1347)
Yohann Loriot (342267), Antoine Hollebecque (15010338), Francesco Facchinetti (9588699), Ken A. Olaussen (14882016), Luc Friboulet (15025943), Christophe Massard (120966), Rastislav Bahleda (13011628)   +6 more
core   +1 more source

A comprehensive overview of selective and novel fibroblast growth factor receptor inhibitors as a potential anticancer modality

Acta Pharmaceutica
The arrival of comprehensive genome sequencing has accelerated the understanding of genetically aberrant advanced cancers and target identification for possible cancer treatment.
Jain Nem Kumar, Tailang Mukul, Thangavel Neelaveni, Makeen Hafiz A., Albratty Mohammed, Najmi Asim, Alhazmi Hassan Ahmad, Zoghebi Khalid, Alagusundaram Muthumanickam, Jain Hemant Kumar, Chandrasekaran Balakumar   +10 more
doaj   +1 more source

Skeletal overgrowth in a pre-pubescent child treated with pan-FGFR inhibitor

Heliyon
Fibroblast growth factors and their receptors (FGFR) have major roles in both human growth and oncogenesis. In adults, therapeutic FGFR inhibitors have been successful against tumors that carry somatic FGFR mutations.
Fataneh Majlessipour, Gaohui Zhu, Nicole Baca, Meenasri Kumbaji, Vivian Hwa, Moise Danielpour   +5 more
doaj   +1 more source

Germline Cancer Predisposition and De Novo Contributions in Pediatric Rhabdomyosarcoma: A Report From the Children's Oncology Group

International Journal of Cancer, EarlyView.
ABSTRACT Approximately 6%–8% of children and adolescents with rhabdomyosarcoma (RMS) have an underlying cancer predisposition disorder (CPD), which varies between embryonal and alveolar subtypes and other clinical characteristics. Identifying a CPD remains challenging, as traditional approaches rely on clinical features and family history. Additionally,
Taylor M. Luckie, Sarah Scollon, Yao Yu, Aniko Sabo, Tiffany Chambers, Olga Taylor, Logan G. Spector, Michael E. Scheurer, Douglas S. Hawkins, Rajkumar Venkatramani, Chad D. Huff, Sharon E. Plon, Philip J. Lupo   +12 more
wiley   +1 more source